Your browser does not support JavaScript! QUADRIGUARD (IVERMECTIN, PYRANTEL PAMOATE, AND PRAZIQUANTEL) TABLET, CHEWABLE [VICAR OPERATING INC.]

Veterinary Medicine Labels  

                Current Medication Information

Options

RxNorm Names

QUADRIGUARD (ivermectin, pyrantel pamoate, and praziquantel) tablet, chewable
[Vicar Operating Inc.]


Category DEA Schedule Marketing Status
PRESCRIPTION ANIMAL DRUG LABEL New Animal Drug Application
Drug Label Sections

For oral use in dogs only.

Caution

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

Description

QuadriGuard™ is a combination of three anthelmintics (ivermectin/pyrantel pamoate/praziquantel). The tablets are available in four sizes in color-coded packages for oral administration to dogs according to their weight (see Dosage).

Indications

For use in dogs to prevent canine heartworm disease by eliminating the tissue stage of heartworm larvae (Dirofilaria immitis) for a month (30 days) after infection and for the treatment and control of roundworms (Toxocara canis, Toxascaris leonina), hookworms (Ancylostoma caninum, Uncinaria stenocephala, Ancylostoma braziliense), and tapeworms (Dipylidium caninum, Taenia pisiformis).

Dosage

QuadriGuard™ (ivermectin/pyrantel pamoate/praziquantel) should be administered orally at monthly intervals at the recommended minimum dose level of 6 mcg of ivermectin per kilogram (2.72 mcg/lb), 5 mg of pyrantel (as pamoate salt) per kg (2.27 mg/lb) and 5 mg of praziquantel per kg (2.27 mg/lb) of body weight, as follows:

Dog Weight Lbs.Chewable Tablet Per MonthTablet SizeIvermectin ContentPyrantel Pamoate ContentPraziquantel Content
6.0 to 121Toy34 mcg28.5 mg28.5 mg
12.1 to 251Small68 mcg57 mg57 mg
25.1 to 501Medium136 mcg114 mg114 mg
50.1 to 1001Large272 mcg228 mg228 mg

QuadriGuard™ is recommended for dogs 8 weeks of age and older. For dogs over 100 lbs, use the appropriate combination of these chewable tablets.

Administration

Remove only one tablet at a time from the foil-backed blister card. Return the remaining tablets to their box to protect the product from light. QuadriGuard™ can be offered to the dog by hand or be added intact to a small amount of dog food. Care should be taken that the dog consumes the complete dose, and the dog should be observed for a few minutes after administration to ensure that part of the dose is not lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended.

QuadriGuard™ should be given at monthly intervals during the period of the year when mosquitoes (vectors), potentially carrying infective heartworm larvae, are active. The initial dose must be given within a month (30 days) after the dog's first exposure to mosquitoes. The final dose must be given within a month (30 days) after the dog's last exposure to mosquitoes.

When replacing another heartworm preventive product in a heartworm disease prevention program, the first dose of QuadriGuard™ must be given within a month (30 days) of the last dose of the former medication. A heartworm test should be performed prior to switching heartworm preventive products.

If the interval between doses exceeds a month (30 days), the efficacy of ivermectin can be reduced. Therefore, for optimal performance, the tablet must be given once a month on or about the same day of the month. If treatment is delayed, whether by a few days or many, immediate treatment with QuadriGuard™ and resumption of the recommended dosing regimen will minimize the opportunity for the development of adult heartworms.

WARNING

For use in dogs only. Keep this and all drugs out of reach of children. In safety studies, testicular hypoplasia was observed in some dogs receiving 3 and 5 times the maximum recommended dose monthly for 6 months (see Animal Safety).

In case of ingestion by humans, clients should be advised to contact a physician immediately. Physicians may contact a Poison Control Center for advice concerning cases of ingestion by humans.

For a copy of the Material Safety Data Sheet (MSDS), or to report adverse reactions, call 1-866-337-5009.

Precautions

Use with caution in sick, debilitated, or underweight animals and dogs weighing less than 10 lbs (see Animal Safety). The safe use of this drug has not been evaluated in pregnant or lactating bitches.

All dogs should be tested for existing heartworm infection before starting treatment with QuadriGuard™, which is not effective against adult D. immitis. Infected dogs should be treated to remove adult heartworms and microfilariae before initiating a heartworm prevention program.

While some microfilariae may be killed by the ivermectin in QuadriGuard™ at the recommended dose level, QuadriGuard™ is not effective for microfilariae clearance. A mild hypersensitivity-type reaction, presumably due to dead or dying microfilariae and particularly involving a transient diarrhea, has been observed in clinical trials with ivermectin alone after treatment of some dogs that have circulating microfilariae.

Adverse Reactions

Self-limiting adverse reactions including lethargy, limpness, salivation, shaking, diarrhea, decreased appetite, licking lips, and belching were reported between 20 minutes and 72 hours following treatment in a field study with QuadriGuard™.

In clinical field trials with ivermectin/pyrantel pamoate, vomiting or diarrhea within 24 hours of dosing was rarely observed (1.1% of administered doses). The following adverse reactions have been reported following the use of ivermectin: depression/lethargy, vomiting, anorexia, diarrhea, mydriasis, ataxia, staggering, convulsions and hypersalivation.

Effectiveness

QuadriGuard™, given orally using the recommended dose and regimen, is effective against the tissue larval stage of D. immitis for a month (30 days) after infection and, as a result, prevent the development of the adult stage. QuadriGuard™ is also effective against canine roundworms (T. canis, T. leonina), hookworms (A. caninum, U. stenocephala, A. braziliense), and tapeworms (T. pisiformis, D. caninum). A total of 61 dogs and puppies with naturally acquired or experimental parasite infections treated with QuadriGuard™ were enrolled in 7 well-controlled laboratory studies to establish effectiveness. These studies included dogs of various sizes, ages and breeds. Data from these studies demonstrated QuadriGuard™ is safe and effective for the removal of the parasite species indicated on the label when used as directed.

Palatability

In a field trial, QuadriGuard™ was shown to be a palatable oral dosage form for dogs.

Animal Safety

Studies with ivermectin indicate that certain dogs of the Collie breed are more sensitive to the effects of ivermectin administered at elevated dose levels (more than 16 times the target use level of 6 mcg/kg) than dogs of other breeds. At elevated doses, sensitive dogs showed adverse reactions which included mydriasis, depression, ataxia, tremors, drooling, paresis, recumbency, excitability, stupor, coma and death. No signs of toxicity were seen at 10 times the recommended dose (27.2 mcg/lb) in sensitive Collies. Results of these studies and bioequivalence studies support the safety of ivermectin products in dogs, including Collies, when used as recommended by the label.

In a target animal safety study, QuadriGuard™ was administered to 8-week-old Beagle puppies at one, three and five times the maximum recommended dose of 12.5 mcg/kg ivermectin, 10.47 mg/kg pyrantel and 10.47 mg/kg praziquantel. The dogs were treated every 30 days for 6 months. Vomiting within 6 hours of dosing and soft or watery feces within 24 hours of dosing were observed. Other observations during the study were: anogenital swelling, lethargy, head movements, shallow, audible or difficult breathing, and salivation. One dog in the 5X group had tremors and decreased activity. All these signs were transient. No treatment was required. Pathology showed testicular hypoplasia in the 3 and 5X groups (see Warnings).

In a laboratory safety study, 12-week-old Beagle puppies receiving 3 and 5 times the recommended dose once weekly for 13 weeks demonstrated a dose-related decrease in testicular maturation compared to controls. In this study, all treated puppies had significantly higher cholesterol levels compared to untreated controls.

In a reproductive safety study, adult males were treated at 37.5 mcg/kg ivermectin, 31.4 mg/kg pyrantel and 31.4 mg/kg praziquantel every 14 days during two full spermatogenic cycles (112 days). The quality of semen and reproductive health were not affected by treatment. Treatment-related vomiting and soft feces were reported during this study.

In a study of the effectiveness of QuadriGuard™ for treatment of T. canis, one 8.1 lb, 72-day-old puppy died 6 days after administration of QuadriGuard™ at the label dose. This puppy and many of the other puppies in the study had high worm burdens and were reported to have diarrhea, sometimes bloody, frequently before and after treatment with QuadriGuard™ or the placebo. Dehydration and signs of anemia (pale mucous membranes) were the only abnormal gross necropsy findings observed. No definitive cause of death was determined. In a 90-day field study, the most serious ADEs (lethargy, limpness, and salivation) were seen in dogs weighing less than 10 lbs(see Precautions).

Storage Information

Store at 20°C-25°C (68°F-77°F), excursions permitted between 15°C-30°C (59°F-86°F). Protect product from light.

How Supplied

QuadriGuard™ is available in four dosage strengths (see dosage section) for dogs of different weights. Each strength comes in a box of 6 chewable tablets, packed 10 boxes per display box.



NADA 141-257, Approved by FDA.
Revised 7/12

Distributed by:
Vicar Operating, Inc.
Los Angeles, CA 90064-1022

All trademarks are the property of their respective owners. All rights reserved.
302097-01

PRINCIPAL DISPLAY PANEL - 6 Tablet Blister Pack Carton - For Dogs 6.0 to 12 lbs.

VETHICAL®

QuadriGuard™
(ivermectin/pyrantel pamoate/praziquantel)

CONTAINS 6 CHEWABLE TABLETS
FOR DOGS 6.0 TO 12 LBS.

Each chewable tablet contains 34 mcg ivermectin,
28.5 mg pyrantel as pamoate salt and 28.5 mg praziquantel.

Administer once a month to prevent
heartworm disease and to treat and
control roundworm, hookworm and
tapeworm infections in dogs.

CAUTION: Federal (U.S.A.) law restricts this drug
to use by or on the order of a licensed veterinarian.

WARNING: For use in dogs only. Keep this and all drugs out of reach of children.
See package insert for complete product safety information.

NADA 141-257, Approved by FDA

PRINCIPAL DISPLAY PANEL - 6 Tablet Blister Pack Carton  - For Dogs 6.0 to 12 lbs.

PRINCIPAL DISPLAY PANEL - 6 Tablet Blister Pack Carton - For Dogs 12.1 to 25 lbs.

VETHICAL®

QuadriGuard™
(ivermectin/pyrantel pamoate/praziquantel)

CONTAINS 6 CHEWABLE TABLETS
FOR DOGS 12.1 TO 25 LBS.

Each chewable tablet contains 68 mcg ivermectin,
57 mg pyrantel as pamoate salt and 57 mg praziquantel.

Administer once a month to prevent
heartworm disease and to treat and
control roundworm, hookworm and
tapeworm infections in dogs.

CAUTION: Federal (U.S.A.) law restricts this drug
to use by or on the order of a licensed veterinarian.

WARNING: For use in dogs only. Keep this and all drugs out of reach of children.
See package insert for complete product safety information.

NADA 141-257, Approved by FDA

PRINCIPAL DISPLAY PANEL - 6 Tablet Blister Pack Carton  - For Dogs 12.1 to 25 lbs.

PRINCIPAL DISPLAY PANEL - 6 Tablet Blister Pack Carton - For Dogs 25.1 to 50 lbs.

VETHICAL®

QuadriGuard™
(ivermectin/pyrantel pamoate/praziquantel)

CONTAINS 6 CHEWABLE TABLETS
FOR DOGS 25.1 TO 50 LBS.

Each chewable tablet contains 136 mcg ivermectin,
114 mg pyrantel as pamoate salt and 114 mg praziquantel.

Administer once a month to prevent
heartworm disease and to treat and
control roundworm, hookworm and
tapeworm infections in dogs.

CAUTION: Federal (U.S.A.) law restricts this drug
to use by or on the order of a licensed veterinarian.

WARNING: For use in dogs only. Keep this and all drugs out of reach of children.
See package insert for complete product safety information.

NADA 141-257, Approved by FDA

PRINCIPAL DISPLAY PANEL - 6 Tablet Blister Pack Carton  - For Dogs 25.1 to 50 lbs.

PRINCIPAL DISPLAY PANEL - 6 Tablet Blister Pack Carton - For Dogs 50.1 to 100 lbs.

VETHICAL®

QuadriGuard™
(ivermectin/pyrantel pamoate/praziquantel)

CONTAINS 6 CHEWABLE TABLETS
FOR DOGS 50.1 TO 100 LBS.

Each chewable tablet contains 272 mcg ivermectin,
228 mg pyrantel as pamoate salt and 228 mg praziquantel.

Administer once a month to prevent
heartworm disease and to treat and
control roundworm, hookworm and
tapeworm infections in dogs.

CAUTION: Federal (U.S.A.) law restricts this drug
to use by or on the order of a licensed veterinarian.

WARNING: For use in dogs only. Keep this and all drugs out of reach of children.
See package insert for complete product safety information.

NADA 141-257, Approved by FDA

PRINCIPAL DISPLAY PANEL - 6 Tablet Blister Pack Carton  - For Dogs 50.1 to 100 lbs.
QUADRIGUARD 
ivermectin, pyrantel pamoate, and praziquantel tablet, chewable
Product Information
Product TypePRESCRIPTION ANIMAL DRUG LABELItem Code (Source)NDC:50386-1014
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Ivermectin (Ivermectin) Ivermectin34 ug
pyrantel pamoate (pyrantel) pyrantel28.5 mg
Praziquantel (Praziquantel) Praziquantel28.5 mg
Product Characteristics
ColorBROWN (Beige speckled) Scoreno score
ShapeROUNDSize10mm
FlavorImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:50386-1014-61 in 1 CARTON
16 in 1 BLISTER PACK
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NADANADA14125710/01/2012
QUADRIGUARD 
ivermectin, pyrantel pamoate, and praziquantel tablet, chewable
Product Information
Product TypePRESCRIPTION ANIMAL DRUG LABELItem Code (Source)NDC:50386-1015
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Ivermectin (Ivermectin) Ivermectin68 ug
pyrantel pamoate (pyrantel) pyrantel57 mg
Praziquantel (Praziquantel) Praziquantel57 mg
Product Characteristics
ColorBROWN (Beige speckled) Scoreno score
ShapeROUNDSize11mm
FlavorImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:50386-1015-61 in 1 CARTON
16 in 1 BLISTER PACK
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NADANADA14125710/01/2012
QUADRIGUARD 
ivermectin, pyrantel pamoate, and praziquantel tablet, chewable
Product Information
Product TypePRESCRIPTION ANIMAL DRUG LABELItem Code (Source)NDC:50386-1016
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Ivermectin (Ivermectin) Ivermectin136 ug
pyrantel pamoate (pyrantel) pyrantel114 mg
Praziquantel (Praziquantel) Praziquantel114 mg
Product Characteristics
ColorBROWN (Beige speckled) Scoreno score
ShapeROUNDSize16mm
FlavorImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:50386-1016-61 in 1 CARTON
16 in 1 BLISTER PACK
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NADANADA14125710/01/2012
QUADRIGUARD 
ivermectin, pyrantel pamoate, and praziquantel tablet, chewable
Product Information
Product TypePRESCRIPTION ANIMAL DRUG LABELItem Code (Source)NDC:50386-1017
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Ivermectin (Ivermectin) Ivermectin272 ug
pyrantel pamoate (pyrantel) pyrantel228 mg
Praziquantel (Praziquantel) Praziquantel228 mg
Product Characteristics
ColorBROWN (Beige speckled) Scoreno score
ShapeROUNDSize19mm
FlavorImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:50386-1017-61 in 1 CARTON
16 in 1 BLISTER PACK
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NADANADA14125710/01/2012
Labeler - Vicar Operating Inc. (052503799)

Revised: 5/2013
 
Vicar Operating Inc.

Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services